Clinical trials: Multiple Myeloma
Multiple Myeloma, Bortezomib
Evaluation of Clinical Treatment of Multiple Myeloma Based on Multi-omics
With the emergence of new drugs, the short-term survival rate of multiple myeloma has been significantly increased. However, in clinical treatment, doctors found that different patients may present different clinical efficacy and…
- Trial name
- NCT04678089
- Testing
- Bortezomib
- Where
- China
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Beijing Chao Yang Hospital
Multiple Myeloma, M Protein
A Cross-sectional Study on the Positive Rate of M Protein Based on a Highly Sensitive Serum M Protein Detection Method.
By using a highly sensitive serum M protein detection method based on the MALDI-TOF MS platform, serum monoclonal immunoglobul (M protein) in detection was performed on the visiting patients to explore the positive rate of serum…
- Trial name
- NCT06082284
- Where
- China
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Zhujiang Hospital
Refractory Multiple Myeloma
A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma
1. Establish the MTD of Lintuzumab-Ac225 as monotherapy 2. Establish overall response rate (ORR) where ORR = CR + sCR+ VGPR+PR) 3. Confirm the safety profile of the treatment regimen 4.
- Trial name
- NCT02998047
- Testing
- Lintuzumab AC 225
- Where
- 5 sites in United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Actinium Pharmaceuticals
Monoclonal Gammopathy, Multiple Myeloma
Multi-center Screening for Serum M Protein
This study aims to utilize a highly sensitive method for detecting M protein in serum to examine the prevalence of M protein in various age groups of individuals aged over 30 who underwent physical examinations in different…
- Conditions
- Monoclonal Gammopathy, Multiple Myeloma, M-protein
- Trial name
- NCT06750965
- Testing
- Serum M protein screening
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Zhujiang Hospital
Multiple Myeloma
A Study to Compare the PK , Safety, and Immunogenicity of QL2109 With Daratumumab in Male Subjects
The goal of this clinical study is to establish the comparability of the pharmacokinetics and similarity of the safety and immunogenicity profiles of QL2109 and Darzalex following a single intravenous infusion in healthy male…
- Trial name
- NCT07400744
- Testing
- QL2109, Darzalex
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Multiple Myeloma
64Cu-LLP2A for Imaging Multiple Myeloma
The investigators are performing a trial with goals to demonstrate the feasibility of imaging multiple myeloma (MM) patients with 64Cu-LLP2A-positron emission tomography (PET)/magnetic resonance (MR).
- Trial name
- NCT03804424
- Testing
- 64Cu-LLP2A, PET/MR, Blood samples for serum stability
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Monoclonal Gammopathy of Undetermined Significance
MGUS/MM Awareness and Genetics Insights Campaign (MAGIC) Screening Study
This study is being done to screen adults for MGUS and to better understand the genetic and immune factors linked to this condition.
- Trial name
- MAGIC (NCT06472830)
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Multiple Myeloma
Efficacy and Safety Evaluation of BCMA-UCART
This trial aims to evaluate the safety and efficacy of BCMA-UCART in treating patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT03752541
- Testing
- BCMA-UCART
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bioray Laboratories
Multiple Myeloma
Psychoeducational and Behavioral Strategies in Reducing Distress and Anxiety in Patients With Multiple Myeloma and Their Family Caregivers
This pilot clinical trial studies how well psychoeducational and behavioral strategies work in reducing distress and anxiety in patients with multiple myeloma and their family caregivers.
- Trial name
- NCT02129569
- Testing
- Psychoeducational intervention, behavioral intervention, counseling intervention
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Case Comprehensive Cancer Center
Multiple Myeloma
A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients
This study assesses the impact of cannabis (also commonly called marijuana, weed, or THC) use on quality of life among patients with multiple myeloma who are receiving chemotherapy.
- Trial name
- NCT07225738
- Testing
- Non-Interventional Study
- Where
- 11 sites in United States
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Multiple Myeloma, Non-Hodgkin Lymphoma
Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL
This is a phase I trial with pilot expansion of HLA-haploidentical or HLA-mismatched related donor nicotinamide expanded-natural killer (NAM-NK) cell based therapy for patients with relapsed or refractory multiple myeloma (MM) or…
- Conditions
- Multiple Myeloma, Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Mantle-Cell Lymphoma
- Trial name
- NCT03019666
- Testing
- Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Masonic Cancer Center, University of Minnesota
Leukemia, Lymphoid, Leukemia, Myeloid
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
This study is examining a chemotherapy regimen and immune suppressive medications in the setting of an allogeneic stem cell transplant.
- Conditions
- Leukemia, Lymphoid, Leukemia, Myeloid, Myelodysplastic Syndromes, Myelofibrosis
- Trial name
- FluBuATG (NCT02916979)
- Testing
- Fludarabine, Busulfan, Rabbit ATG
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Dartmouth-Hitchcock Medical Center
Leukemia (Both ALL and AML), Cancer of Lung
Changing Over Time of Ascorbic Acid After Chemotherapy
Rationale: Recent studies showed that ascorbic acid (AA) stimulates proliferation and maturation of T lymphocytes and NK cells. Chemotherapy results in depletion of those cells and thereby an increased infection rate.
- Conditions
- Leukemia (Both ALL and AML), Cancer of Lung, Myeloma
- Trial name
- NCT02931942
- Testing
- blood withdrawn
- Where
- Netherlands
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Healthy
Predicting Progression of Developing Myeloma in a High-Risk Screened Population and General Population
We will seek consent from participants to use the data and biospecimens collected according study protocol to address additional research questions for MGUS, SMM, MM, and other conditions.
- Trial name
- NCT05837884
- Testing
- blood sampling
- Where
- 4 sites in Israel
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Tel-Aviv Sourasky Medical Center
Myeloproliferative Disorders, Lymphoproliferative Disorders
In Vitro Drug Sensitivity Testing of Fresh Human Samples
Hematological malignancies gather several various pathologies included myeloproliferative disorders (as acute myeloid leukemia (AML) or chronic myeloid leukemia (CML)) and lymphoproliferative disorders (as chronic lymphoid…
- Trial name
- ESAAC (NCT05001386)
- Testing
- Blood collection for the evaluation of the anti-drugs sensitivity
- Where
- 2 sites in France
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Multiple Myeloma
Role of Osteocytes in Myeloma Bone Disease
Progress in the treatment of myeloma and myeloma bone disease has substantially increased overall survival, but relapse is inevitable and better treatment is needed.
- Trial name
- NCT02212262
- Where
- 2 sites in United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Attaya Suvannasankha
Haematological Malignancy, Leukemia, Acute
Rehabilitation Needs of the Malaysian Haematological Cancer Survivors
Many cancers are being treated more effectively nowadays due to the raised awareness and early detection as well as advancement in researches and technology.
- Conditions
- Haematological Malignancy, Leukemia, Acute, Lymphoma, Myeloma Multiple
- Trial name
- NCT04236063
- Testing
- WHODAS 2.0 Questionnaire
- Where
- Malaysia
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- University of Malaya
Myeloma, Endometrial Cancer
Positron Emission Tomography (PET) Imaging Studies With NIS Reporter
The goal of this proposal is to perform first-in-man evaluation of and experimental imaging agent F-18 tetrafluoroborate (BF4) or (TFB).
- Trial name
- NCT02907073
- Testing
- BF4
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Multiple Myeloma
Value of Macrophage-Colony Stimulating Factor as a New Marker of Bone Lesions in Multiple Myeloma
The Primary objective of this study is to compare serum levels of Macrophage-Colony Stimulating Factor (M-CSF) in a population of patients with multiple myeloma (MM), in a population of patients with Monoclonal Gammopathy of…
- Trial name
- MCSF-MYELOME (NCT02800954)
- Testing
- blood samples, Bone marow samples
- Where
- 3 sites in France
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Monoclonal Gammopathy of Undetermined Significance (MGUS), Intestinal Flora
Characteristics and Clinical Significance of Gut Microbiota in Patients With Monoclonal Gammopathy
This is an observational case-control study, aiming to systematically analyze the gut microbiome characteristics of patients with monoclonal gammopathy of undetermined significance (MGUS).
- Conditions
- Monoclonal Gammopathy of Undetermined Significance (MGUS), Intestinal Flora, Multiple Myeloma, M-Protein
- Trial name
- NCT06690593
- Where
- China
- Volunteers
- 2,990 people, healthy volunteers welcome
- Sponsor
- Zhujiang Hospital